SEATTLE, March 6 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced that it plans to issue earnings results for the fourth quarter and year ended Dec. 31, 2007, after the close of market on March 13, 2008. The company's earnings conference call will take place March 13, 2008, at 2 p.m. PDT (5 p.m. EDT).
Third-Quarter Earnings Conference Call: 2 p.m. PDT / 5 p.m. EDT, March 13, 2008
Participants are invited to call 877-545-1491 or 719-325-4931. The live event will be available on Trubion's Web site at http://investors.trubion.com/events.cfm.
A replay of the discussion can be obtained beginning at 8 p.m. EDT March 13 by visiting Trubion's Web site or calling 888-203-1112 or 719-457-0820 and entering the code 7634379. The telephone replay will be available until midnight on Monday, March 17, 2008.
Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain polypeptide protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's lead product candidate, TRU-015, has completed a Phase 2b clinical trial for the treatment of rheumatoid arthritis, and is also in development under the Wyeth collaboration for the treatment of non-Hodgkin's lymphoma, Systemic Lupus Erythematosus and other undisclosed indications.
Trubion's proprietary product candidate, TRU-016, is a novel
CD37-targeted therapy for the treatment of B-cell malignancies currently in
Phase 1 clinical evaluation. In addition to Trubion's current product
candidates, the company is also developing additional alliance and
proprietary product candidates that build on its product development
experience. More information is available in the investors section of
Trubion's website: investors.trubion.com.
Senior Director, Corporate Communications
Trubion Pharmaceuticals, Inc.
Waggener Edstrom Worldwide Healthcare
Senior Vice President
|SOURCE Trubion Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved